About the VIP Study
The von Willebrand factor in pregnancy (VIP) study
The VIP Study is a prospective, multicenter, investigator-initiated
cohort study in the US (NCT04146376).
The study is being coordinated by
Dr. Jill Johnsen, Dr. Barbara Konkle and Dr. Peter Kouides.
Aim of the VIP study
The VIP Study aims to increase our understanding of how best to manage bleeding during delivery and the postpartum period in women with von Willebrand disease (VWD).
It will assess the impact of maintaining von Willebrand factor (VWF) levels at a specific target level using VWF replacement therapy on bleeding rates during and after childbirth.
Study design
The study will include pregnant women with von Willebrand disease Type 1 (with VWF level < 30%), Type 2 or Type 3. Participants will be assigned to one of two study groups based on their VWF activity level in the third trimester of pregnancy:
- Correctors: Those with VWF activity ≥ 100%
- Non-correctors: Those with VWF activity < 100%
The Non-corrector group will receive VWF replacement therapy with the aim of raising VWF plasma levels to 100–150% during delivery and 50–100% for a period after delivery. The Corrector group will not receive VWF replacement therapy. Both groups will receive prophylaxis with antifibrinolytic therapy (tranexamic acid).